belzutifan (Welireg)

Indications

• cancers associated with von Hippel-Lindau disease
  • renal cell carcinomas
  • CNS hemangioblastomas
  • pancreatic neuroendocrine tumors

Dosage

• once daily continued until disease progression

Pharmacokinetics

• median time to treatment response is 8.2 months

Adverse effects

• anemia (90%), an on-target effect of the drug
• fatigue (66%), headache (41%), dizziness (39%), nausea (34%), dyspnea (23%), hypertension (> 8%)

Mechanism of action

• targets hypoxia-inducible factor 2-alpha

More general terms

• antineoplastic agent (chemotherapeutic agent)